We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+69.49%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$617M
AUM Growth
–
Cap. Flow
+$516M
Cap. Flow %
83.64%
Top 10 Hldgs %
46.54%
Holding
114
New
114
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$16.4M
2
CHMA
Chiasma, Inc. Common Stock
CHMA
+$5.74M
3
IMVT icon
Immunovant
IMVT
+$5.65M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.43M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.34M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 16.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$93.5M 15.16%
+754,900
New +$67.6M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$33.3M 5.39%
+350,000
New +$30.3M
GILD icon
3
CALL
Gilead Sciences
GILD
$162B
$32.5M 5.26%
+500,000
New +$32.6M
ITCI
4
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$31.7M 5.14%
+924,100
New +$11.1M
IBB icon
5
PUT
iShares Biotechnology ETF
IBB
$9.36B
$30.1M 4.88%
+250,000
New +$27.9M
ALLK
6
CALL
DELISTED
Allakos
ALLK
$15.1M 2.45%
+158,800
New +$14M
SRPT icon
7
CALL
Sarepta Therapeutics
SRPT
$1.67B
$13.2M 2.15%
+102,600
New +$10.4M
MRTX
8
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.9M 2.09%
+100,000
New +$9.65M
ONC
9
PUT
BeOne Medicines Ltd
ONC
$33.9B
$12.8M 2.07%
+77,000
New +$12.8M
GOSS icon
10
PUT
Gossamer Bio
GOSS
$65.2M
$12.1M 1.95%
+771,100
New +$15.5M
BHVN
11
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.9M 1.76%
+200,000
New +$9.9M
GWPH
12
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$10.5M 1.69%
+100,000
New +$11.2M
ARQL
13
CALL
DELISTED
Arqule Inc
ARQL
$9.93M 1.61%
+497,700
New +$5.77M
AUPH icon
14
Aurinia Pharmaceuticals
AUPH
$1.96B
$9.75M 1.58%
+481,104
New +$4.43M
ASND icon
15
CALL
Ascendis Pharma A/S
ASND
$16.9B
$9.65M 1.56%
+69,400
New +$7.71M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$9.6M 1.56%
+133,000
New +$16.4M
IMMU
17
CALL
DELISTED
Immunomedics Inc
IMMU
$9.48M 1.54%
+448,200
New +$7.91M
ITCI
18
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.16M 1.48%
+267,100
New +$3.21M
MDGL icon
19
PUT
Madrigal Pharmaceuticals
MDGL
$12.6B
$9.11M 1.48%
+100,000
New +$9.7M
APLS
20
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$8.79M 1.42%
+286,900
New +$7.94M
ICPT
21
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$8.04M 1.3%
+64,900
New +$5.81M
IMVT icon
22
Immunovant
IMVT
$8.01B
$8M 1.3%
+504,117
New +$5.65M
GBT
23
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.95M 1.29%
+100,000
New +$5.93M
ZGNX
24
PUT
DELISTED
Zogenix, Inc.
ZGNX
$7.73M 1.25%
+148,200
New +$6.79M
CRSP icon
25
PUT
CRISPR Therapeutics
CRSP
$4.61B
$7.53M 1.22%
+123,700
New +$6.75M
1
2 3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Ikarian Capital, which disclosed 114 positions worth $617M. Its ten largest holdings account for 47% of the portfolio.

Its largest position is Sage Therapeutics: 133,000 shares worth $9.6M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets.

  • Ikarian Capital's largest Q4 2019 buy was Sage Therapeutics: 133,000 shares worth $9.6M.
  • Ikarian Capital's ten largest holdings make up 47% of its $617M portfolio in Q4 2019.
  • Ikarian Capital disclosed 114 positions in Q4 2019, its first 13F filing on record.

Based on Ikarian Capital's 13F filing for Q4 2019, filed 31 Jan 2020.